Iovance Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary

Iovance Biotherapeutics

28/02/2024 22:44

* Iovance Biotherapeutics Inc  IOVA.OQ  reported a quarterly
adjusted loss of 45 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -64 cents.  The mean expectation of
fourteen analysts for the quarter was for a loss of 43 cents per
share. Wall Street expected results to range from -48 cents
to -34 cents per share.
    * Revenue was $482.00 thousand​; analysts expected $1.39
million. 
    * Iovance Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 46 cents​.
    * The company reported a quarterly loss of $118.14 million.
    * Iovance Biotherapeutics Inc shares had risen by 114.9%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.8%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Iovance
Biotherapeutics Inc is $24.50 

This summary was machine generated from LSEG data February 28 at
10:43 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.43          -0.45          Missed
 Sep. 30 2023      -0.45          -0.46          Missed
 Jun. 30 2023      -0.80          -0.47          Beat
 Mar. 31 2023      -0.74          -0.50          Beat